Integra has announced Vialink - a pipette management tool that allows users to simply create and manage custom programs, maintain a service history, and transfer firmware upgrade details between Viaflo electronic pipettes and your PC.
The U.S. Food and Drug Administration has purchased the FlowCAM particle imaging and analysis system from laboratory instrumentation manufacturer Fluid Imaging Technologies.
Research teams have discovered that the SHARPIN protein regulates human cell activity. Recent study concludes that SHARPIN regulates the movement and activity of inflammatory cells and of lung and prostate cancer cells.
Pantarhei Bioscience announces the publication of the results of an innovative treatment strategy for ovarian cancer. Pantarhei Bioscience is developing the zona pellucida protein 3 antigen as immunisation strategy against ovarian cancer.
The TB Alliance announces the launch of a collaboration with the National Institute of Allergy and Infectious Diseases’ AIDS Clinical Trial Group to conduct and help complete a Phase 3 clinical trial testing potentially faster-acting tuberculosis treatments.
Amarin Corporation plc announced data from its Phase 3 clinical trial that showed patients with high triglycerides who were also on statin therapy experienced a significant reduction in triglyceride levels and other lipid parameters.
Gilead Sciences Inc. and Johnson & Johnson's Tibotec unit said they will collaborate to develop a new HIV pill that combines Tibotec's Prezista with Gilead's drug Emtriva and two experimental drugs.
Geron Corp. is exiting the field it pioneered in a calculated business move that underscores the long, costly path embryonic stem cells face to become real-world products.
The nation's fastest campus supercomputer, built at Purdue University, is being used for a variety of research projects, including cancer stem cell studies.
Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder.
Midatech received Swissmedic approval to start a clinical trial with insulin-coated gold nanoparticles.
Anavex Life Sciences announced the completion of its Phase 1 single ascending dose clinical trial of Anavex 2-73, the company’s lead drug candidate for the treatment of Alzheimer’s.
Abbott’s National Heart, Lung and Blood Institute reported its final results for its Aim-High study.
Concert Pharmaceuticals Inc. has entered a research collaboration with The National Institutes of Health Therapeutics for Rare and Neglected Diseases program.